Federico Albrecht, MD

home / authors / federico-albrecht-md

Federico Albrecht, M.D., is an oncologist/hematologist at Miami Cancer Institute, a part of Baptist Health South Florida. Acoording to Baptist Health South Florida, Albrecht received his medical degree from the Universidad del Salvador, in Buenos Aires, Argentina. After graduating from Universidad del Salvador , Albrecht completed an internship and residency in internal medicine at the University of Miami/Jackson Memorial Hospital, where he also completed a fellowship in hematology/oncology and was the senior fellow. Albrecht is Board-certified in medical oncology.

Articles

Patient Case: 67-Year Old Female With Advanced SCLC

Patient Case: 67-Year Old Female With Advanced SCLC

February 5th 2024

Federico Albrecht, MD, discusses the challenging case of a 67-year-old heavy smoker who presented with small cell lung cancer.

Optimizing SCLC Outcomes with Early Action

Optimizing SCLC Outcomes with Early Action

February 2nd 2024

Federico Albrecht, MD, discusses Miami Cancer Institute's specific protocol for hospitalized patients with small cell lung cancer.

Early Detection, Treatment, and Prognosis are Key in SCLC

Early Detection, Treatment, and Prognosis are Key in SCLC

January 23rd 2024

Federico Albrecht, MD, discusses the standard practice on testing for a patient with small cell lung cancer at Miami Cancer Institute.

Lessons from Real-World Cases of Small Cell Lung Cancer

Lessons from Real-World Cases of Small Cell Lung Cancer

August 15th 2023

In season 4, episode 12 of Targeted Talks, Federico Albrecht, MD, gives and account of 2 cases of patients with small cell lung cancer and how these patients were treated.

Studies Supporting the Use of PD-L1 Therapy Plus Chemo in ES-SCLC

Studies Supporting the Use of PD-L1 Therapy Plus Chemo in ES-SCLC

August 13th 2023

Federico Albrecht, MD, comments on clinical trials supporting the use of PD-L1 inhibitor therapy in combination with standard chemotherapy for the treatment of patients with extensive-stage small cell lung cancer.